Literature DB >> 10952568

Contribution of a thickened cell wall and its glutamine nonamidated component to the vancomycin resistance expressed by Staphylococcus aureus Mu50.

L Cui1, H Murakami, K Kuwahara-Arai, H Hanaki, K Hiramatsu.   

Abstract

Staphylococcus aureus Mu50, which has reduced susceptibility to vancomycin, has a remarkably thickened cell wall with an increased proportion of glutamine nonamidated muropeptides. In addition, Mu50 had enhanced glutamine synthetase and L-glutamine D-fructose-6-phosphate aminotransferase activities, which are involved in the cell-wall peptidoglycan synthesis pathway. Furthermore, significantly increased levels of incorporation of (14)C-labeled D-glucose into the cell wall was observed in Mu50. Unlike a femC mutant S. aureus strain, increased levels of production of nonamidated muropeptides in Mu50 was not caused by lower levels of glutamine synthetase activity but was considered to be due to the glutamine depletion caused by increased glucose utilization by the cell to biosynthesize increased amounts of peptidoglycan. After the cells were allowed to synthesize cell wall in the absence or presence of glucose and glutamine, cells with different cell-wall thicknesses and with cell walls with different levels of cross-linking were prepared, and susceptibility testing of these cells demonstrated a strong correlation between the cell-wall thickness and the degree of vancomycin resistance. Affinity trapping of vancomycin molecules by the cell wall and clogging of the outer layers of peptidoglycan by bound vancomycin molecules were considered to be the mechanism of vancomycin resistance of Mu50. The reduced cross-linking and the increased affinity of binding to vancomycin of the Mu50 cell wall presumably caused by the increased proportion of nonamidated muropeptides may also contribute to the resistance to some extent.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10952568      PMCID: PMC90058          DOI: 10.1128/AAC.44.9.2276-2285.2000

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  31 in total

1.  Analysis of vancomycin population susceptibility profiles, killing activity, and postantibiotic effect against vancomycin-intermediate Staphylococcus aureus.

Authors:  J R Aeschlimann; E Hershberger; M J Rybak
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

2.  Identification of the up- and down-regulated genes in vancomycin-resistant Staphylococcus aureus strains Mu3 and Mu50 by cDNA differential hybridization method.

Authors:  M Kuroda; K Kuwahara-Arai; K Hiramatsu
Journal:  Biochem Biophys Res Commun       Date:  2000-03-16       Impact factor: 3.575

3.  Glycopeptide resistance in staphylococci.

Authors:  K Hiramatsu; H Hanaki
Journal:  Curr Opin Infect Dis       Date:  1998-12       Impact factor: 4.915

4.  Increase in glutamine-non-amidated muropeptides in the peptidoglycan of vancomycin-resistant Staphylococcus aureus strain Mu50.

Authors:  H Hanaki; H Labischinski; Y Inaba; N Kondo; H Murakami; K Hiramatsu
Journal:  J Antimicrob Chemother       Date:  1998-09       Impact factor: 5.790

5.  Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin.

Authors:  K Hiramatsu; N Aritaka; H Hanaki; S Kawasaki; Y Hosoda; S Hori; Y Fukuchi; I Kobayashi
Journal:  Lancet       Date:  1997-12-06       Impact factor: 79.321

6.  Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.

Authors:  K Hiramatsu; H Hanaki; T Ino; K Yabuta; T Oguri; F C Tenover
Journal:  J Antimicrob Chemother       Date:  1997-07       Impact factor: 5.790

7.  Improved tools for biological sequence comparison.

Authors:  W R Pearson; D J Lipman
Journal:  Proc Natl Acad Sci U S A       Date:  1988-04       Impact factor: 11.205

8.  Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides.

Authors:  F C Tenover; M V Lancaster; B C Hill; C D Steward; S A Stocker; G A Hancock; C M O'Hara; S K McAllister; N C Clark; K Hiramatsu
Journal:  J Clin Microbiol       Date:  1998-04       Impact factor: 5.948

9.  Inhibition of cell wall turnover and autolysis by vancomycin in a highly vancomycin-resistant mutant of Staphylococcus aureus.

Authors:  K Sieradzki; A Tomasz
Journal:  J Bacteriol       Date:  1997-04       Impact factor: 3.490

10.  The peptidoglycan composition of a Staphylococcus aureus mutant selected for reduced methicillin resistance.

Authors:  A Ornelas-Soares; H de Lencastre; B de Jonge; D Gage; Y S Chang; A Tomasz
Journal:  J Biol Chem       Date:  1993-12-15       Impact factor: 5.157

View more
  108 in total

1.  Nationwide survey shows that methicillin-resistant Staphylococcus aureus strains heterogeneously and intermediately resistant to vancomycin are not disseminated throughout Japanese hospitals.

Authors:  Y Ike; Y Arakawa; X Ma; K Tatewaki; M Nagasawa; H Tomita; K Tanimoto; S Fujimoto
Journal:  J Clin Microbiol       Date:  2001-12       Impact factor: 5.948

2.  Transcriptional induction of the penicillin-binding protein 2 gene in Staphylococcus aureus by cell wall-active antibiotics oxacillin and vancomycin.

Authors:  Susan Boyle-Vavra; Shaohui Yin; Mamatha Challapalli; Robert S Daum
Journal:  Antimicrob Agents Chemother       Date:  2003-03       Impact factor: 5.191

3.  A report on the first case of vancomycin-intermediate Staphylococcus aureus (VISA) in Hawai'i.

Authors:  Suttirak Chaiwongkarjohn; Pornpoj Pramyothin; Nuntra Suwantarat; Matthew J Bankowski; Terrie Koyamatsu; Steven E Seifried; Erlaine F Bello
Journal:  Hawaii Med J       Date:  2011-11

4.  Teicoplanin stress-selected mutations increasing sigma(B) activity in Staphylococcus aureus.

Authors:  M Bischoff; B Berger-Bächi
Journal:  Antimicrob Agents Chemother       Date:  2001-06       Impact factor: 5.191

5.  Intact mutS in laboratory-derived and clinical glycopeptide-intermediate Staphylococcus aureus strains.

Authors:  Arunachalam Muthaiyan; Radheshyam K Jayaswal; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

6.  Linezolid in VAP by MRSA: a better choice?

Authors:  Malina Ioanas; Hartmut Lode
Journal:  Intensive Care Med       Date:  2004-02-06       Impact factor: 17.440

7.  Cell wall composition and decreased autolytic activity and lysostaphin susceptibility of glycopeptide-intermediate Staphylococcus aureus.

Authors:  Jennifer L Koehl; Arunachalam Muthaiyan; Radheshyam K Jayaswal; Kerstin Ehlert; Harald Labischinski; Brian J Wilkinson
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Staphylococcus aureus isolates with reduced susceptibility to glycopeptides belong to accessory gene regulator group I or II.

Authors:  Isabelle Verdier; Marie-Elisabeth Reverdy; Jerome Etienne; Gérard Lina; Michèle Bes; François Vandenesch
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191

9.  Coordinated phenotype switching with large-scale chromosome flip-flop inversion observed in bacteria.

Authors:  Longzhu Cui; Hui-min Neoh; Akira Iwamoto; Keiichi Hiramatsu
Journal:  Proc Natl Acad Sci U S A       Date:  2012-05-29       Impact factor: 11.205

10.  daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Warren E Rose; Steven N Leonard; George Sakoulas; Glenn W Kaatz; Marcus J Zervos; Anjly Sheth; Christopher F Carpenter; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2007-11-12       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.